VJHemOnc is committed to improving our service to you

MPN Advances Day 2019 | Ropeginterferon alfa-2b for polycythemia vera: impacts and considerations

VJHemOnc is committed to improving our service to you

Jean-Jacques Kiladjian

From the Myeloproliferative Neoplasms Advances Day 2019 in London, UK, Jean-Jacques Kiladjian, MD, PhD, Saint-Louis Hospital, University of Paris, Paris, France, discusses the impacts of ropeginterferon alfa-2b treatment for polycythemia vera (PV). He also highlights the consideration that this treatment is not suitable for everyone.

Share this video  

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter